文献速递老年与多病共存慢病管理预防保健、筛查与疫苗

他汀用于75岁以上无心血管病人群一级预防的回顾性队列研究

Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study.
PubMed 文献 · BMJ · 2018-09-05

基于西班牙SIDIAP基层医疗数据库2006-15年46 864名≥75岁无临床动脉粥样硬化性心血管病人群的回顾性队列研究,按是否合并2型糖尿病及是否新用他汀分层,采用倾向评分校正的Cox模型分析。无糖尿病者他汀使用与动脉粥样硬化性心血管病及全因死亡均无显著关联;合并糖尿病者75-84岁他汀使用与两项结局显著降低相关,该效应在85岁后明显减弱、90岁以上消失。

要点

  • 无糖尿病的75岁以上老人,他汀一级预防未见动脉粥样硬化性心血管病或全因死亡获益
  • 合并2型糖尿病的75-84岁老人他汀使用与心血管病及全因死亡风险降低相关
  • 合并糖尿病者他汀获益在85岁后明显减弱,90岁以上消失

核心结论

  • 在74岁以上无2型糖尿病者中,他汀治疗与动脉粥样硬化性心血管病及全因死亡减少无关,即使其心血管病发生率高于提议使用他汀的风险阈值。
  • 合并糖尿病时他汀使用与动脉粥样硬化性心血管病发生率和全因死亡显著降低相关,但该效应在85岁后减弱、90岁以上消失。

研究设计与样本

  • 西班牙加泰罗尼亚基层医疗系统SIDIAP数据库2006-15年的回顾性队列研究。
  • 纳入46 864名≥75岁无临床确诊动脉粥样硬化性心血管病者,按2型糖尿病与否及他汀非使用者/新使用者分层。
  • 采用倾向评分校正的Cox比例风险模型比较动脉粥样硬化性心血管病与全因死亡发生率,并以分类(75-84岁、≥85岁)和连续(样条、加性Cox模型)方式评估年龄与他汀效应的关系。

主要发现

  • 队列平均年龄77岁,女性占63%,中位随访5.6年。
  • 无糖尿病者75-84岁他汀使用对动脉粥样硬化性心血管病的HR为0.94(95%CI 0.86-1.04),全因死亡为0.98(0.91-1.05)。
  • 无糖尿病者≥85岁他汀使用对动脉粥样硬化性心血管病的HR为0.93(95%CI 0.82-1.06),全因死亡为0.97(0.90-1.05)。
  • 合并糖尿病者75-84岁他汀使用对动脉粥样硬化性心血管病的HR为0.76(95%CI 0.65-0.89),全因死亡为0.84(0.75-0.94);≥85岁分别为0.82(0.53-1.26)和1.05(0.86-1.28)。
  • 连续尺度样条分析显示无糖尿病者74岁以上他汀对两项结局均缺乏获益,合并糖尿病者他汀有保护效应但85岁后明显减弱、90岁以上消失。

关键数值与推荐

  • 无糖尿病75-84岁:动脉粥样硬化性心血管病HR 0.94(95%CI 0.86-1.04),全因死亡HR 0.98(0.91-1.05)。
  • 无糖尿病≥85岁:动脉粥样硬化性心血管病HR 0.93(95%CI 0.82-1.06),全因死亡HR 0.97(0.90-1.05)。
  • 合并糖尿病75-84岁:动脉粥样硬化性心血管病HR 0.76(95%CI 0.65-0.89),全因死亡HR 0.84(0.75-0.94)。
  • 合并糖尿病≥85岁:动脉粥样硬化性心血管病HR 0.82(95%CI 0.53-1.26),全因死亡HR 1.05(0.86-1.28)。

临床怎么用

  • 对75岁以上无糖尿病者启动他汀作一级预防前,应与患者讨论缺乏获益证据,避免仅凭风险阈值决策。
  • 对75-84岁合并2型糖尿病者,他汀一级预防与心血管病及全因死亡风险降低相关,可支持个体化使用。
  • 对85岁以上尤其90岁以上合并糖尿病者,不应默认他汀获益持续存在,需个体化评估并复核用药指征。

局限性

  • 为回顾性队列研究,存在适应证混杂等观察性设计固有局限,尽管已用倾向评分校正。
  • 研究对象为西班牙加泰罗尼亚基层医疗数据库人群,外推至其他地区与人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether statin treatment is associated with a reduction in atherosclerotic cardiovascular disease (CVD) and mortality in old and very old adults with and without diabetes. DESIGN: Retrospective cohort study. SETTING: Database of the Catalan primary care system (SIDIAP), Spain, 2006-15. PARTICIPANTS: 46 864 people aged 75 years or more without clinically recognised atherosclerotic CVD. Participants were stratified by presence of type 2 diabetes mellitus and as statin non-users or new users. MAIN OUTCOME MEASURES: Incidences of atherosclerotic CVD and all cause mortality compared using Cox proportional hazards modelling, adjusted by the propensity score of statin treatment. The relation of age with the effect of statins was assessed using both a categorical approach, stratifying the analysis by old (75-84 years) and very old (≥85 years) age groups, and a continuous analysis, using an additive Cox proportional hazard model. RESULTS: The cohort included 46 864 participants (mean age 77 years; 63% women; median follow-up 5.6 years). In participants without diabetes, the hazard ratios for statin use in 75-84 year olds were 0.94 (95% confidence interval 0.86 to 1.04) for atherosclerotic CVD and 0.98 (0.91 to 1.05) for all cause mortality, and in those aged 85 and older were 0.93 (0.82 to 1.06) and 0.97 (0.90 to 1.05), respectively. In participants with diabetes, the hazard ratio of statin use in 75-84 year olds was 0.76 (0.65 to 0.89) for atherosclerotic CVD and 0.84 (0.75 to 0.94) for all cause mortality, and in those aged 85 and older were 0.82 (0.53 to 1.26) and 1.05 (0.86 to 1.28), respectively. Similarly, effect analysis of age in a continuous scale, using splines, corroborated the lack of beneficial statins effect for atherosclerotic CVD and all cause mortality in participants without diabetes older than 74 years. In participants with diabetes, statins showed a protective effect against atherosclerotic CVD and all cause mortality; this effect was substantially reduced beyond the age of 85 years and disappeared in nonagenarians. CONCLUSIONS: In participants older than 74 years without type 2 diabetes, statin treatment was not associated with a reduction in atherosclerotic CVD or in all cause mortality, even when the incidence of atherosclerotic CVD was statistically significantly higher than the risk thresholds proposed for statin use. In the presence of diabetes, statin use was statistically significantly associated with reductions in the incidence of atherosclerotic CVD and in all cause mortality. This effect decreased after age 85 years and disappeared in nonagenarians.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Ramos R, Comas-Cufí M, Martí-Lluch R, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ. 2018. PMID: 30185425. doi:10.1136/bmj.k3359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。